Luspatercept-aamt (Reblozyl)

Reblozyl (luspatercept‑aamt) is covered for anemia in adults (≥18) with beta thalassemia who require regular RBC transfusions (including transfusion‑dependent patients) and is not supported for patients <18, those not requiring regular transfusions, or off‑label uses. Coverage requires hematologist prescribing/consultation, initial approval for 4 months (renewal 12 months) with renewal contingent on a clinically meaningful decrease in transfusion burden, documentation of diagnosis/transfusion history, and dosing ≤1.25 mg/kg SC no more frequently than every 3 weeks.

"Treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions."

Sign up to see full coverage criteria, indications, and limitations.